Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Vaccines

Free Subscription Articles published in PLoS Med Retrieve available abstracts of 43 articles: HTML format

Single Articles

June 2022
1. TAKUVA S, Takalani A, Seocharan I, Yende-Zuma N, et al
   Safety evaluation of the single-dose Ad26.COV2.S vaccine among healthcare workers in the Sisonke study in South Africa: A phase 3b implementation trial.
   PLoS Med. 2022;19:e1004024.
   PubMed     Abstract available
   
   
   
2. WONG CKH, Lau KTK, Xiong X, Au ICH, et al
   Adverse events of special interest and mortality following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines in Hong Kong: A retrospective study.
   PLoS Med. 2022;19:e1004018.
   PubMed     Abstract available
   
   
   May 2022
3. JIN P, Guo X, Chen W, Ma S, et al
   Safety and immunogenicity of heterologous boost immunization with an adenovirus type-5-vectored and protein-subunit-based COVID-19 vaccine (Convidecia/ZF2001): A randomized, observer-blinded, placebo-controlled trial.
   PLoS Med. 2022;19:e1003953.
   PubMed     Abstract available
   
   
   
4. MARTIN CA, Pan D, Melbourne C, Teece L, et al
   Risk factors associated with SARS-CoV-2 infection in a multiethnic cohort of United Kingdom healthcare workers (UK-REACH): A cross-sectional analysis.
   PLoS Med. 2022;19:e1004015.
   PubMed     Abstract available
   
   
   
5. PEARSON CAB, Bozzani F, Procter SR, Davies NG, et al
   Correction: COVID-19 vaccination in Sindh Province, Pakistan: A modelling study of health impact and cost-effectiveness.
   PLoS Med. 2022;19:e1003990.
   PubMed     Abstract available
   
   
   
6. VAN GILS MJ, Lavell A, van der Straten K, Appelman B, et al
   Antibody responses against SARS-CoV-2 variants induced by four different SARS-CoV-2 vaccines in health care workers in the Netherlands: A prospective cohort study.
   PLoS Med. 2022;19:e1003991.
   PubMed     Abstract available
   
   
   
7. QIAN G, Toizumi M, Clifford S, Le LT, et al
   Association of pneumococcal carriage in infants with the risk of carriage among their contacts in Nha Trang, Vietnam: A nested cross-sectional survey.
   PLoS Med. 2022;19:e1004016.
   PubMed     Abstract available
   
   
   April 2022
8. FOO D, Sarna M, Pereira G, Moore HC, et al
   Prenatal influenza vaccination and allergic and autoimmune diseases in childhood: A longitudinal, population-based linked cohort study.
   PLoS Med. 2022;19:e1003963.
   PubMed     Abstract available
   
   
   
9. WATKINSON RE, Williams R, Gillibrand S, Sanders C, et al
   Correction: Ethnic inequalities in COVID-19 vaccine uptake and comparison to seasonal influenza vaccine uptake in Greater Manchester, UK: A cohort study.
   PLoS Med. 2022;19:e1003982.
   PubMed     Abstract available
   
   
   March 2022
10. WATKINSON RE, Williams R, Gillibrand S, Sanders C, et al
    Ethnic inequalities in COVID-19 vaccine uptake and comparison to seasonal influenza vaccine uptake in Greater Manchester, UK: A cohort study.
    PLoS Med. 2022;19:e1003932.
    PubMed     Abstract available
    
    
    February 2022
11. SAAKSVUORI L, Betsch C, Nohynek H, Salo H, et al
    Information nudges for influenza vaccination: Evidence from a large-scale cluster-randomized controlled trial in Finland.
    PLoS Med. 2022;19:e1003919.
    PubMed     Abstract available
    
    
    
12. 
    Vaccine equity: A fundamental imperative in the fight against COVID-19.
    PLoS Med. 2022;19:e1003948.
    PubMed    
    
    
    
13. KERR S, Joy M, Torabi F, Bedston S, et al
    First dose ChAdOx1 and BNT162b2 COVID-19 vaccinations and cerebral venous sinus thrombosis: A pooled self-controlled case series study of 11.6 million individuals in England, Scotland, and Wales.
    PLoS Med. 2022;19:e1003927.
    PubMed     Abstract available
    
    
    
14. WHITELEY WN, Ip S, Cooper JA, Bolton T, et al
    Association of COVID-19 vaccines ChAdOx1 and BNT162b2 with major venous, arterial, or thrombocytopenic events: A population-based cohort study of 46 million adults in England.
    PLoS Med. 2022;19:e1003926.
    PubMed     Abstract available
    
    
    
15. MCQUAID F, Mulholland R, Sangpang Rai Y, Agrawal U, et al
    Uptake of infant and preschool immunisations in Scotland and England during the COVID-19 pandemic: An observational study of routinely collected data.
    PLoS Med. 2022;19:e1003916.
    PubMed     Abstract available
    
    
    January 2022
16. GENTILE I, Schiano Moriello N
    COVID-19 prophylaxis in immunosuppressed patients: Beyond vaccination.
    PLoS Med. 2022;19:e1003917.
    PubMed     Abstract available
    
    
    
17. ANYWAINE Z, Barry H, Anzala O, Mutua G, et al
    Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in children and adolescents in Africa: A randomised, placebo-controlled, multicentre Phase II clinical trial.
    PLoS Med. 2022;19:e1003865.
    PubMed     Abstract available
    
    
    December 2021
18. GRAM MA, Nielsen J, Schelde AB, Nielsen KF, et al
    Vaccine effectiveness against SARS-CoV-2 infection, hospitalization, and death when combining a first dose ChAdOx1 vaccine with a subsequent mRNA vaccine in Denmark: A nationwide population-based cohort study.
    PLoS Med. 2021;18:e1003874.
    PubMed     Abstract available
    
    
    
19. PETERSEN M, Schwab J, Havlir DV
    SARS-CoV-2 vaccine boosters: The time to act is now.
    PLoS Med. 2021;18:e1003882.
    PubMed     Abstract available
    
    
    November 2021
20. MARTIN CA, Marshall C, Patel P, Goss C, et al
    SARS-CoV-2 vaccine uptake in a multi-ethnic UK healthcare workforce: A cross-sectional study.
    PLoS Med. 2021;18:e1003823.
    PubMed     Abstract available
    
    
    
21. BHANU C, Gopal DP, Walters K, Chaudhry UAR, et al
    Vaccination uptake amongst older adults from minority ethnic backgrounds: A systematic review.
    PLoS Med. 2021;18:e1003826.
    PubMed     Abstract available
    
    
    October 2021
22. PEARSON CAB, Bozzani F, Procter SR, Davies NG, et al
    COVID-19 vaccination in Sindh Province, Pakistan: A modelling study of health impact and cost-effectiveness.
    PLoS Med. 2021;18:e1003815.
    PubMed     Abstract available
    
    
    
23. FORMICA N, Mallory R, Albert G, Robinson M, et al
    Different dose regimens of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373) in younger and older adults: A phase 2 randomized placebo-controlled trial.
    PLoS Med. 2021;18:e1003769.
    PubMed     Abstract available
    
    
    
24. ISANAKA S, Garba S, Plikaytis B, McNeal MM, et al
    Correction: Immunogenicity of an oral rotavirus vaccine administered with prenatal nutritional support in Niger: A cluster randomized clinical trial.
    PLoS Med. 2021;18:e1003776.
    PubMed     Abstract available
    
    
    
25. BARRY H, Mutua G, Kibuuka H, Anywaine Z, et al
    Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in healthy and HIV-infected adults: A randomised, placebo-controlled Phase II clinical trial in Africa.
    PLoS Med. 2021;18:e1003813.
    PubMed     Abstract available
    
    
    
26. GENG EH, Reid MJA, Goosby E, Abdool-Karim Q, et al
    COVID-19 and global equity for health: The good, the bad, and the wicked.
    PLoS Med. 2021;18:e1003797.
    PubMed     Abstract available
    
    
    September 2021
27. FIGUEROA JP, Hotez PJ, Batista C, Ben Amor Y, et al
    Achieving global equity for COVID-19 vaccines: Stronger international partnerships and greater advocacy and solidarity are needed.
    PLoS Med. 2021;18:e1003772.
    PubMed     Abstract available
    
    
    
28. KROGSGAARD LW, Petersen I, Plana-Ripoll O, Bech BH, et al
    Infections in temporal proximity to HPV vaccination and adverse effects following vaccination in Denmark: A nationwide register-based cohort study and case-crossover analysis.
    PLoS Med. 2021;18:e1003768.
    PubMed     Abstract available
    
    
    
29. NAGATA JM, Epstein A, Ganson KT, Benmarhnia T, et al
    Drought and child vaccination coverage in 22 countries in sub-Saharan Africa: A retrospective analysis of national survey data from 2011 to 2019.
    PLoS Med. 2021;18:e1003678.
    PubMed     Abstract available
    
    
    August 2021
30. CHAN J, Gidding HF, Blyth CC, Fathima P, et al
    Levels of pneumococcal conjugate vaccine coverage and indirect protection against invasive pneumococcal disease and pneumonia hospitalisations in Australia: An observational study.
    PLoS Med. 2021;18:e1003733.
    PubMed     Abstract available
    
    
    
31. ISANAKA S, Garba S, Plikaytis B, Malone McNeal M, et al
    Immunogenicity of an oral rotavirus vaccine administered with prenatal nutritional support in Niger: A cluster randomized clinical trial.
    PLoS Med. 2021;18:e1003720.
    PubMed     Abstract available
    
    
    
32. BINES JE
    Investigating barriers to the protective efficacy provided by rotavirus vaccines in African infants.
    PLoS Med. 2021;18:e1003721.
    PubMed     Abstract available
    
    
    July 2021
33. ISANAKA S, Langendorf C, McNeal MM, Meyer N, et al
    Rotavirus vaccine efficacy up to 2 years of age and against diverse circulating rotavirus strains in Niger: Extended follow-up of a randomized controlled trial.
    PLoS Med. 2021;18:e1003655.
    PubMed     Abstract available
    
    
    June 2021
34. GRAY P, Kann H, Pimenoff VN, Eriksson T, et al
    Human papillomavirus seroprevalence in pregnant women following gender-neutral and girls-only vaccination programs in Finland: A cross-sectional cohort analysis following a cluster randomized trial.
    PLoS Med. 2021;18:e1003588.
    PubMed     Abstract available
    
    
    
35. MAO W, Ogbuoji O, Watkins D, Bharali I, et al
    Achieving global mortality reduction targets and universal health coverage: The impact of COVID-19.
    PLoS Med. 2021;18:e1003675.
    PubMed     Abstract available
    
    
    May 2021
36. GOLDMAN M, Hermans C
    Thrombotic thrombocytopenia associated with COVID-19 infection or vaccination: Possible paths to platelet factor 4 autoimmunity.
    PLoS Med. 2021;18:e1003648.
    PubMed     Abstract available
    
    
    April 2021
37. KRISHNAN A, Dar L, Saha S, Narayan VV, et al
    Efficacy of live attenuated and inactivated influenza vaccines among children in rural India: A 2-year, randomized, triple-blind, placebo-controlled trial.
    PLoS Med. 2021;18:e1003609.
    PubMed     Abstract available
    
    
    March 2021
38. KIM JJ, Simms KT, Killen J, Smith MA, et al
    Human papillomavirus vaccination for adults aged 30 to 45 years in the United States: A cost-effectiveness analysis.
    PLoS Med. 2021;18:e1003534.
    PubMed     Abstract available
    
    
    February 2021
39. JEAN K, Raad H, Gaythorpe KAM, Hamlet A, et al
    Assessing the impact of preventive mass vaccination campaigns on yellow fever outbreaks in Africa: A population-level self-controlled case series study.
    PLoS Med. 2021;18:e1003523.
    PubMed     Abstract available
    
    
    
40. KLEYNHANS J, Tempia S, Shioda K, von Gottberg A, et al
    Estimated impact of the pneumococcal conjugate vaccine on pneumonia mortality in South Africa, 1999 through 2016: An ecological modelling study.
    PLoS Med. 2021;18:e1003537.
    PubMed     Abstract available
    
    
    November 2020
41. HOGAN AB, Winskill P, Ghani AC
    Estimated impact of RTS,S/AS01 malaria vaccine allocation strategies in sub-Saharan Africa: A modelling study.
    PLoS Med. 2020;17:e1003377.
    PubMed     Abstract available
    
    
    October 2020
42. LAWRENCE H, Pick H, Baskaran V, Daniel P, et al
    Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against vaccine serotype pneumococcal pneumonia in adults: A case-control test-negative design study.
    PLoS Med. 2020;17:e1003326.
    PubMed     Abstract available
    
    
    
43. BAUMGAERTNER B, Ridenhour BJ, Justwan F, Carlisle JE, et al
    Risk of disease and willingness to vaccinate in the United States: A population-based survey.
    PLoS Med. 2020;17:e1003354.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Vaccines is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: